Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049857 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1POLBGAA | |
| SCHEMBL2684159 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL197024 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL14284025 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1POLBGAA | |
| SCHEMBL10170624 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL31404936 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL3135737 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1GAACFTR | |
| SCHEMBL14761801 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1POLBGAA | |
| SCHEMBL22899009 | 0.81 | CYP19A1 (0.51) | SMN1; SMN2LMNAL3MBTL1POLBGAA | |
| SCHEMBL19319049 | 0.81 | TBXAS1 (0.50) | SMN1; SMN2LMNAL3MBTL1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105154463-A | Construction and application of strains of over-expression Tm-AHAS-CSU | UNIV NORTHWESTERN | 2015-12-16 | — | — | CN | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SMN1; SMN2 4709/4885LMNA 4285/4885L3MBTL1 2276/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SMN1; SMN2 4709/4885LMNA 4285/4885L3MBTL1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.